Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schulin, T.
Right arrow Articles by Eliopoulos, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schulin, T.
Right arrow Articles by Eliopoulos, G. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 42, 297-301, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

In-vitro activity of the new ketolide antibiotic HMR 3647 against gram- positive bacteria

T Schulin, CB Wennersten, RC Moellering Jr and GM Eliopoulos
Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02115, USA.

The comparative in-vitro activity of HMR 3647, a new ketolide antibiotic, was investigated against 492 clinical isolates of gram- positive bacteria, including multiply resistant strains, by an agar- dilution technique. All streptococci tested were inhibited by the new ketolide at concentrations < or = 0.5 mg/L. HMR 3647 was more potent than erythromycin against staphylococci. For enterococci the new compound yielded an MIC90 of 8 mg/L. Erysipelothrix spp., Pediococcus spp., Leuconostoc spp., Lactobacillus spp., JK diphtheroids and Listeria monocytogenes were also susceptible to the new ketolide.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. Liu and S. Douthwaite
Activity of the Ketolide Telithromycin Is Refractory to Erm Monomethylation of Bacterial rRNA
Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1629 - 1633.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
F.-J. Schmitz, J. Petridou, H. Jagusch, N. Astfalk, S. Scheuring, and S. Schwarz
Molecular characterization of ketolide-resistant erm(A)-carrying Staphylococcus aureus isolates selected in vitro by telithromycin, ABT-773, quinupristin and clindamycin
J. Antimicrob. Chemother., April 1, 2002; 49(4): 611 - 617.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Pihlajamaki, J. Kataja, H. Seppala, J. Elliot, M. Leinonen, P. Huovinen, and J. Jalava
Ribosomal Mutations in Streptococcus pneumoniae Clinical Isolates
Antimicrob. Agents Chemother., March 1, 2002; 46(3): 654 - 658.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Jalava, J. Kataja, H. Seppälä, and P. Huovinen
In Vitro Activities of the Novel Ketolide Telithromycin (HMR 3647) against Erythromycin-Resistant Streptococcus Species
Antimicrob. Agents Chemother., March 1, 2001; 45(3): 789 - 793.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
K. V. Singh, K. K. Zscheck, and B. E. Murray
Efficacy of Telithromycin (HMR 3647) against Enterococci in a Mouse Peritonitis Model
Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3434 - 3437.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.